HIV protease inhibitors: Recent clinical trials and recommendations on use

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 10, 2009, Pages 1615-1629

  Fernández Montero, José Vicente ^a   Barreiro, Pablo ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Antiretroviral therapy; Atazanavir; Darunavir; Drug resistance; HIV; Protease inhibitors; Tipranavir

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIDEPRESSANT AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR PLUS RITONAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; PROTEINASE INHIBITOR; RIBAVIRIN; RIFAMYCIN; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; JAUNDICE; LIPODYSTROPHY; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; PHARMACOGENETICS; PR INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SUBCUTANEOUS FAT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; METABOLOME; OLIGOPEPTIDES; PYRIDINES; PYRONES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 67650511438     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902980202     Document Type: Review

References (112)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality in an ambulatory HIV-infected population. N Engl J Med 1998;338:853-860 (Pubitemid 28135961)
2. Detels R, Tarwater P, Phair J, et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infection before and after AIDS diagnosis. AIDS 2001;15:347-355
3. Carr A, Samaras K, Chisholm D, Cooper D. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998;351:1881-1883 (Pubitemid 28279721)
4. Walli R, Herfort O, Michl G, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:167-173
5. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV cohort study. Circulation 1999;100:700-705
6. Kwara A, De Long A, Rezk N, et al. Antiretroviral drug concentrations and HIV-RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008;46:719-725
7. Lowe S, Wensing A, Droste J, et al. No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations. HIV Clin Trials 2006;7:285-290
8. Nath A, Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 2006;19:358-361 (Pubitemid 44246409)
9. Wire M, Shelton M, Studenberg S. Fosamprenavir. Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006;45:137-168
10. Cvetkovic R, Goa K. Lopinavir/ritonavir: a review of its use in the mamagement of HIV infection. Drugs 2003;63:769-802 (Pubitemid 36432083)
11. Sekar V, Spinosa-Guzman S, Lefebvre E, et al. Clinical pharmacology of TMC-114: a new HIV protease inhibitor [abstract TUPE0083]. 16th International AIDS Conference; august 2006, Toronto, Canada
12. Zeldin R, Petruschke R. Pharmacological and therapeutic properties of ritonavir boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9 (Pubitemid 38072176)
13. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of health and human services. November 3, 2008. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf •• Current guidelines for the use of antiretrovirals both in treatment-naïve and experienced patients.
14. Ford J, Khoo S, Back J. Intracellular pharmacology of antiretroviral protease inhibitors. J Antimicrob Chemother 2004;54:982-990 (Pubitemid 40136729)
15. Fromm M. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000;38:69-74 (Pubitemid 30077981)
16. Huisman M, Smit J, Crommentuyn K, et al. Multidrug resistance protein 2 transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002;16:2295-2301
17. Sax P, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004;37:1111-1124 (Pubitemid 39166645)
18. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir vs. nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046 (Pubitemid 34680595)
19. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-655 • Head to head comparison of two boosted protease inhibitor based regimens for initial therapy.
20. Clotet B, Bellos N, Molina JM, et al; on behalf of the POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178 • Registration trial for darunavir
21. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357(9256):592-598
22. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13(10):F63-70
23. Colby-Germinario SP, Cammalleri C, Germinario RJ. L6 myotubes: the effects of antiretroviral protease inhibitors on sugar transport and cellular glucose transporters [abstract 48]. 3th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 2001
24. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005;19:685-694
25. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006;20:711-718 • Head to head comparison of two boosted protease inhibitor based regimens for initial therapy.
26. Danner S, Carr A, Leonard J, et al. A short-term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-1533
27. Hall C, Raines C, Barmett S, et al. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS 1999;13:1207-1212
28. Dragsted U, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antiviral Ther 2005;10:735-743
29. Walmsley S, Ruxrungtham K, Slim J, et al. Saquinavir/r BID versus lopinavir/r BID plus emtricitabine/tenofovir QD as initial therapy in HIV-1 infected patients: the Gemini study [abstract PS1/4]. 11th European AIDS Conference. October 24-27, 2007; Madrid, Spain
30. Gill M, Beall G, Beattie D, et al. Safety of saquinavir soft-gel capsule (SQV-SGC) in combination with other antiretroviral agents: multicenter study NV15182: 24 week analysis [abstract I-90]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 12-15, 2007; Toronto, Canada.
31. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000;238:74-80 (Pubitemid 30038386)
32. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per cubic milimetre or less. N Engl J Med 1997;337:725-733 (Pubitemid 27417971)
33. Gulick R, Hu X, Fiscus S, et al. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir or both in HIV-infected adults with virologic failure on indinavir: AIDS clinical trials group study 359. J Infect Dis 2000;182:1375-1382 (Pubitemid 30800941)
34. Murphy R, da Silva B, McMillan F, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2008;9:1-10 • Lenghtier study available of long-term exposure to LPV/r.
35. Riddler S, Haubrich R, Di Rienzo G, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106 (Pubitemid 351679596)
36. Haubrich R, Riddler S, Di Rienzo G, et al. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI, and NNRTI-sparing regimens for initial treatment of HIV-1 infection [abstract 38]. 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007; Los Angeles, USA
37. Barreiro P, Garcia-Benayas T, Soriano V, Gallant J. Simplification of antiretroviral treatment-how to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Rev 2002;4:233-241 (Pubitemid 36104234)
38. Johnson M, Gathe J, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006;43:153-160 (Pubitemid 44454808)
39. Klein C, Chiu Y, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007;44:401-410 (Pubitemid 46555374)
40. Cameron D, da Silva B, Arribas J, et al. A 96-weeks comparison of lopinavir-ritonavir combination therapy by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008;198:234-240. • Head to head comparison of first-line protease inhibitor vs. non-nucleoside analog-based regimens.
41. Lundgren J, Reiss P, Worm S, et al. Risk of Myocardial Infarction with Exposure to Specific ARV from the PI, NNRTI, and NRTI Drug Classes: The D:A:D Study. 16th Conference on Retroviruses and Opprtunistic infections [abstract 44LB]. Montreal, Canada. February 2009
42. Walmsley S, Rodriguez-French A, Boghossian J, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;35:22-32 (Pubitemid 38044778)
43. Gathe J, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once daily fosamprenavir/ritonavir versus twice daily nelfinavir in naïve HIV-1 infected patients. AIDS 2004;18:1529-1537
44. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir- ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006;368:476-482 • Head to head comparison of two boosted protease inhibitor based regimens for initial therapy.
45. Youle M. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. J Antimicrob Chemother 2007;60:1195-1205 (Pubitemid 350176278)
46. Jimenez-Nacher I, Garcia B, Barreiro P, et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 2008;62:816-822
47. Rivas P, Morello J, Garrido C, et al. Role of atazanavir in the treatment of HIV infection. Ther Clin Risk Manag 2009;5:1-18
48. Rodriguez-Novoa S, Morello J, Gonzalez M, et al. Increase in serum bilirubin in HIV/hepatitis C virus coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin. AIDS 2008;22:2535-2537
49. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005;39(2):174-180 (Pubitemid 40741115)
50. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr 2003;32:18-29 (Pubitemid 36091481)
51. Murphy R, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. AIDS 2003;17:2603-2614
52. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose ZDV and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004;36:1011-1019 (Pubitemid 38989366)
53. Malan D, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naïve patients. J Acquir Immune Defic Syndr 2008;47:161-167 (Pubitemid 351172182)
54. Soriano V, de Rossi L. A review of the atazanavir, ritonavir, tenofovir, emtricitabine and nevirapine trial. Eur Infect Dis In press
55. Haas D, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003;17:1339-1349
56. Cohen C, Nieto-Cisneros L, Zala C, et al. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005;21:1683-1692
57. Soriano V, García-Gasco P, Vispo E, et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008;61:200-205 • Study to validate atazanavir as simplification PI.
58. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis 2007;44:1484-1492 • Study to validate atazanavir as simplification PI.
59. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006;296:806-814
60. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the atazanavir-ritonavir monomaintenance (ATARITMO) trial. AIDS 2007;21:1309-1315
61. Poppe S, Slade D, Chong K, et al. Antiviral activity of the dihydropyrone PNU-140690, a new non-peptidic HIV protease inhibitor. Antimicrob Agents Chemother 1997;41:1058-1063
62. De Mendoza C, Morelló J, Garcia-Gascó P, et al. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. Expert Opin Pharmacother 2007;8:839-850
63. Gathe J, Kohlbrenner V, Pierone G, et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple PI experienced patients: BI 1182.52. 10th Conference on Retroviruses and Opportunistic Infections [abstract 179]. February 6-10, 2003; Boston, USA
64. Nwando O, Themba B. An open-label steady state investigation of the pharmacokinetics of tipranavir and ritonavir and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers [abstract TuPe7.8C01]. 3rd IAS Conference on HIV Pathogenesis and Treatment. July 24-27, 2005; Rio de Janeiro, Brazil
65. Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007;45:761-769 (Pubitemid 47381280)
66. Wang Y, Daenzer C, Wood R, et al. The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor in Phase II study in antiretroviral naïve HIV-infected patients [abstract 673]. 7th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2000; San Francisco, USA
67. Cooper D, Zajnderverg R, Ruxrungthan K, et al. Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naïve patients [abstract PL13.4]. Results of BI 1182.33. 8th International Congress on Drug Therapy in HIV Infection. November, 12-16, 2006; Glasgow, UK
68. Neubacher D, Markowitz M, Slater L, et al. Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2) [abstract 7.2/3]. 9th European AIDS Conference. October 25-29, 2003; Warsaw, Poland
69. Gathe J, Cooper D, Frathing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006;43:1337-1346 • Registration trial for tipranavir.
70. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-Week results of the RESIST-2 trial. Clin Infect Dis 2006;43:1347-1356 • Registration trial for tipranavir.
71. Hicks C, Cahn P, Cooper D, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-475
72. Walmsley S, Katlama K, Lazzarin A, Arestéh K. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients. J Acquir Immune Defic Syndr 2008;47:429-440
73. Graff J, von Hentig N, Kuczka K, et al. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J Antimicrob Chemother 2008;61:394-399
74. Lefebvre E, Schiffer C. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev 2008;10:131-142
75. Surleaux D, Tahri A, Verschueren W, et al. Discovery and selection of TMC-114: a next generation HIV-1 protease inhibitor. J Med Chem 2005;48:1813-1822 (Pubitemid 40396314)
76. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007;47:479-484 (Pubitemid 46465961)
77. Fenton C, Perry C. Darunavir in the treatment of HIV-1 infection. Drugs 2007;67:2791-2801
78. Rawizza H, Sax P. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases. AIDS Read 2008;18:466-472
79. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007;21:395-402 • Registration trial for darunavir.
80. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of darunavir/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11-8
81. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients. 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007;46:24-31 (Pubitemid 47514614)
82. Madruga J, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007;370:49-58
83. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007;8:259-264 (Pubitemid 46691696)
84. Ortiz R, De Jesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS 2008;22:1389-1397
85. Shen L, Peterson S, Sedaghat A, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008;14:762-766
86. Le Moing V, Thieabaut R, Chene G, et al. Predictors of long-term increase in CD4 + cell counts in HIV-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002;185:471-480 (Pubitemid 34142809)
87. Ledergerber B, Lundgren J, Walker A, et al. Predictors of trend in CD4 + T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral drug classes. Lancet 2004;364:51-62
88. van Leeuwen R, Katlama C, Murphy R, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003;17:987-999
89. Ghani A, Henley W, Donnelly C, et al. Comparison of the effectiveness of non-nucleoside reverse traasncriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001;15:1133-1142
90. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naïve patients (the Combine study). Antivir Ther 2002;7:81-90
91. Benito JM, Lopez M, Martin JC, et al. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or non-nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 2002;18:1379-1388
92. Phenix B, Lum J, Nie Z, et al. Anti-apoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001;98:1078-1085
93. Chavan S, Kodoth S, Pahwa R, Pahwa S. The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood 2001;98:383-389
94. Martinez-Picado J, Savara A, Shi L, et al. Fitness of HIV-1 protease inhibitor-selected single mutants. Virology 2000;275:318-322
95. Stoddart C, Liegler T, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001;7:712-718
96. Barreiro P, Soriano V, Casas E, Gonzalez-Lahoz J. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. AIDS 2002;16:245-249 (Pubitemid 34118572)
97. Best B, Letendre S, Brigid E, et al. Low atazanavir concentration sin cerebrospinal fluid. AIDS 2009;23:83-87
98. Erickson J, Eissenstat M, Silva A, et al. Design and crystal structure of SPI-256: an experimental HIV protease inhibitor with a high genetic barrier to resistance [abstract H-1266]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 25-28, 2008; Washington DC, USA
99. Wynne B, Holland A, Ruff D, Guttendorf R. A first-in-human study evaluating the safety, tolerability, and pharmacokinetics of SPI-256, a novel HIV protease Inhibitor, administered alone and in combination with ritonavir in healthy adult subjects [abstract H-1265]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 25-28, 2008; Washington DC, USA
100. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 2008;68:567-578
101. Gingelmaier A, Kurowski M, Kästner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006;20:1737-1743
102. Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr In press
103. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy:pharmacokinetics and placental transfer. AIDS 2007;21:2409-2415
104. Sabin C, Worm S, on behalf of the D:A:D study group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-1426
105. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-1193
106. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005;6:421-425 (Pubitemid 41723310)
107. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, openlabel, multicentre study. AIDS 2001;15:1811-1822
108. Pulido F, Arribas JR, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005;40:280-287 (Pubitemid 41533067)
109. Pulido F, Arribas JR, Delgado R, et al.; for the OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008;22:F1-9
110. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naïve HIV-infected patients. AIDS 2008;22:385-393
111. Sahali S, Chaix ML, Delfraissy JF, Ghosn J. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev 2008;10:4-14
112. Gathe J, Yeh R, Mayberry C, et al. Single agent therapy with lopinavir/ritonavir suppresses HIV-1 viral replication in ARV naïve patients: IMANI II- 96 week final results [abstract H-1241]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. October 25-28, 2008; Washington DC, USA